^
Association details:
Biomarker:ADRM1 overexpression
Cancer:Breast Cancer
Drug:bortezomib (Proteasome inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

773 / 1 - Inhibition of ubiquitin receptor ADRM1 for the treatment of metastatic breast cancer

Published date:
03/09/2022
Excerpt:
The objective of this study is to verify the role of ubiquitin receptor RPN13/ADRM1 in metastatic breast cancer samples of European American and African American patients and identify the safe combination of regimens of bortezomib in combination with Up289 to mitigate recurrence, metastasis and reduce mortality in AA TNBC/QNBC...ADRM1 expression is highly expressed in AA versus EA breast cancer patients, resulting in a worse overall survival.